Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.
Interferon beta treatment of multiple sclerosis increases serum interleukin-7.
Daytime sleepiness versus fatigue in patients with multiple sclerosis: A systematic review on the Epworth sleepiness scale as an assessment tool.
Timing of birth and risk of multiple sclerosis: population based study.
Diplomatic Assistance: Can Helminth-Modulated Macrophages Act as Treatment for Inflammatory Disease?
Sex hormones and multiple sclerosis: another informative failure.
Effect of therapeutic horseback riding on balance and gait of people with multiple sclerosis.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse Remitting Multiple Sclerosis
Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed.
A monoclonal natural human IgM protects axons in the absence of remyelination.
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis.
Genzyme receives positive CHMP opinion for LEMTRADA™ (alemtuzumab) in Europe
Autoimmune sleep disorders.
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA TM*) in Multiple Sclerosis
Specific inhibition of secreted NRG1 types I-II by heparin enhances Schwann Cell myelination.
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Associations Between Fatigue and Disability, Functional Mobility, Depression, and Quality of Life in People with Multiple Sclerosis.
Laquinimod in Relapsing-Remitting Multiple Sclerosis
A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients.
Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis.
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids.
Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study.
CHMP issues positive opinion for TECFIDERA™ (dimethyl fumarate) as a first-line treatment for multiple sclerosis in the European Union
Standing up in multiple sclerosis (SUMS): protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis.

Pages